| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 0.87 [0.76, 1.00] | | < 1 | | 0% | 2 studies (2/-) | 97.2 % | some concern | not evaluable | moderate | crucial | - |
| progression or deaths (PFS) | 0.78 [0.63, 0.97] | | < 1 | | 0% | 1 study (1/-) | 98.8 % | NA | not evaluable | | important | - |
| objective responses (ORR) | 1.17 [0.87, 1.57] | | > 1 | | 0% | 2 studies (2/-) | 85.5 % | low | not evaluable | high | non important | - |
safety endpoints 00 |
| AE (any grade) | 2.22 [1.12, 4.38] | | < 1 | | 0% | 1 study (1/-) | 1.1 % | NA | not evaluable | | non important | - |
| AE (grade 3-4) | 1.84 [1.35, 2.52] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
| AE leading to death (grade 5) | 1.55 [0.86, 2.78] | | < 1 | | 0% | 2 studies (2/-) | 7.3 % | some concern | not evaluable | moderate | non important | - |
| AE leading to treatment discontinuation (any grade) | 7.09 [0.06, 791.12] | | < 1 | | 91% | 2 studies (2/-) | 21.4 % | low | not evaluable | high | non important | - |
| SAE (any grade) | 3.19 [2.19, 4.65] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
| STRAE (any grade) | 1.24 [0.85, 1.81] | | < 1 | | 0% | 1 study (1/-) | 12.9 % | NA | not evaluable | | non important | - |
| TRAE (any grade) | 0.82 [0.11, 5.85] | | < 1 | | 0% | 1 study (1/-) | 57.9 % | NA | not evaluable | | non important | - |
| TRAE (grade 3-4) | 1.41 [0.93, 2.12] | | < 1 | | 0% | 1 study (1/-) | 5.3 % | NA | not evaluable | | non important | - |
| TRAE leading to death (grade 5) | 7.00 [0.86, 57.23] | | < 1 | | 0% | 1 study (1/-) | 3.6 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Adrenal insufficiency TRAE (grade 3-4) | 5.93 [0.30, 118.96] | | < 1 | | 0% | 1 study (1/-) | 12.5 % | NA | not evaluable | | non important | - |
| Arthralgia TRAE (grade 3-4) | 1.44 [0.48, 4.34] | | < 1 | | 0% | 1 study (1/-) | 26.0 % | NA | not evaluable | | non important | - |
| Asthenia TRAE (grade 3-4) | 2.47 [0.45, 13.60] | | < 1 | | 0% | 1 study (1/-) | 15.1 % | NA | not evaluable | | non important | - |
| Blood creatinine increased TRAE (grade 3-4) | 0.61 [0.02, 18.27] | | < 1 | | 0% | 1 study (1/-) | 61.1 % | NA | not evaluable | | non important | - |
| Chorioretinopathy TRAE (grade 3-4) | 0.61 [0.02, 18.27] | | < 1 | | 0% | 1 study (1/-) | 61.1 % | NA | not evaluable | | non important | - |
| Decreased appetite TRAE (grade 3-4) | 0.30 [0.01, 6.77] | | < 1 | | 0% | 1 study (1/-) | 77.1 % | NA | not evaluable | | non important | - |
| Diarrhoea TRAE (grade 3-4) | 0.53 [0.16, 1.76] | | < 1 | | 0% | 1 study (1/-) | 84.8 % | NA | not evaluable | | non important | - |
| Dry skin TRAE (grade 3-4) | 4.92 [0.22, 109.67] | | < 1 | | 0% | 1 study (1/-) | 16.0 % | NA | not evaluable | | non important | - |
| Erythema TRAE (grade 3-4) | 7.41 [0.37, 148.78] | | < 1 | | 0% | 1 study (1/-) | 9.8 % | NA | not evaluable | | non important | - |
| Eye disorders TRAE (grade 3-4) | 0.98 [0.02, 49.62] | | < 1 | | 0% | 1 study (1/-) | 50.4 % | NA | not evaluable | | non important | - |
| Fatigue TRAE (grade 3-4) | 3.70 [0.38, 35.82] | | < 1 | | 0% | 1 study (1/-) | 13.1 % | NA | not evaluable | | non important | - |
| Hepatitis TRAE (grade 3-4) | 3.94 [0.18, 87.81] | | < 1 | | 0% | 1 study (1/-) | 19.6 % | NA | not evaluable | | non important | - |
| Hyperthyroidism TRAE (grade 3-4) | 4.92 [0.22, 109.67] | | < 1 | | 0% | 1 study (1/-) | 16.0 % | NA | not evaluable | | non important | - |
| Increased lipase level TRAE (grade 3-4) | 0.99 [0.64, 1.52] | | < 1 | | 0% | 1 study (1/-) | 52.3 % | NA | not evaluable | | non important | - |
| Maculopapular rash TRAE (grade 3-4) | 1.36 [0.78, 2.37] | | < 1 | | 0% | 1 study (1/-) | 14.1 % | NA | not evaluable | | non important | - |
| Myalgia TRAE (grade 3-4) | 2.46 [0.22, 27.26] | | < 1 | | 0% | 1 study (1/-) | 23.4 % | NA | not evaluable | | non important | - |
| Nausea TRAE (grade 3-4) | 0.17 [0.02, 1.40] | | < 1 | | 0% | 1 study (1/-) | 94.9 % | NA | not evaluable | | non important | - |
| Pancreatitis TRAE (grade 3-4) | 5.93 [0.30, 118.96] | | < 1 | | 0% | 1 study (1/-) | 12.5 % | NA | not evaluable | | non important | - |
| Peripheral oedema TRAE (grade 3-4) | 1.22 [0.02, 61.84] | | < 1 | | 0% | 1 study (1/-) | 46.1 % | NA | not evaluable | | non important | - |
| Pneumonitis TRAE (grade 3-4) | 4.92 [0.22, 109.67] | | < 1 | | 0% | 1 study (1/-) | 16.0 % | NA | not evaluable | | non important | - |
| Pruritus TRAE (grade 3-4) | 2.46 [0.22, 27.26] | | < 1 | | 0% | 1 study (1/-) | 23.4 % | NA | not evaluable | | non important | - |
| Pyrexia TRAE (grade 3-4) | 1.22 [0.24, 6.13] | | < 1 | | 0% | 1 study (1/-) | 40.3 % | NA | not evaluable | | non important | - |
| Rash TRAE (grade 3-4) | 0.98 [0.53, 1.81] | | < 1 | | 0% | 1 study (1/-) | 53.2 % | NA | not evaluable | | non important | - |
| Vomiting TRAE (grade 3-4) | 0.48 [0.09, 2.52] | | < 1 | | 0% | 1 study (1/-) | 80.5 % | NA | not evaluable | | non important | - |
AE (grade 3-4) endpoints 00 |
| Abdominal pain AE (grade 3-4) | 4.04 [1.13, 14.45] | | < 1 | | 0% | 1 study (1/-) | 1.6 % | NA | not evaluable | | non important | - |
| Asthenia AE (grade 3-4) | 0.10 [0.01, 1.78] | | < 1 | | 0% | 1 study (1/-) | 94.0 % | NA | not evaluable | | non important | - |
| Constipation AE (grade 3-4) | 0.98 [0.14, 7.01] | | < 1 | | 0% | 1 study (1/-) | 50.7 % | NA | not evaluable | | non important | - |
| Cough AE (grade 3-4) | 1.97 [0.07, 58.81] | | < 1 | | 0% | 1 study (1/-) | 35.0 % | NA | not evaluable | | non important | - |
| Decreased appetite AE (grade 3-4) | 14.32 [1.87, 109.52] | | < 1 | | 0% | 1 study (1/-) | 0.5 % | NA | not evaluable | | non important | - |
| Dyspnoea AE (grade 3-4) | 4.00 [0.84, 18.98] | | < 1 | | 0% | 1 study (1/-) | 4.1 % | NA | not evaluable | | non important | - |
| Fatigue AE (grade 3-4) | 3.90 [1.44, 10.57] | | < 1 | | 0% | 1 study (1/-) | 0.4 % | NA | not evaluable | | non important | - |
| Headache AE (grade 3-4) | 1.97 [0.18, 21.82] | | < 1 | | 0% | 1 study (1/-) | 29.2 % | NA | not evaluable | | non important | - |
| Hypothyroidism AE (grade 3-4) | 1.22 [0.02, 61.84] | | < 1 | | 0% | 1 study (1/-) | 46.1 % | NA | not evaluable | | non important | - |
| Nausea AE (grade 3-4) | 1.39 [0.61, 3.18] | | < 1 | | 0% | 1 study (1/-) | 21.7 % | NA | not evaluable | | non important | - |
| Neutropenia AE (grade 3-4) | 0.03 [0.00, 0.19] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
| Peripheral oedema AE (grade 3-4) | 4.97 [0.58, 42.77] | | < 1 | | 0% | 1 study (1/-) | 7.3 % | NA | not evaluable | | non important | - |
| Pruritus AE (grade 3-4) | 5.93 [0.30, 118.96] | | < 1 | | 0% | 1 study (1/-) | 12.5 % | NA | not evaluable | | non important | - |
| Pyrexia AE (grade 3-4) | 7.94 [0.42, 150.76] | | < 1 | | 0% | 1 study (1/-) | 8.6 % | NA | not evaluable | | non important | - |
| Rash AE (grade 3-4) | 7.00 [0.86, 57.23] | | < 1 | | 0% | 1 study (1/-) | 3.6 % | NA | not evaluable | | non important | - |
| Thrombocytopenia AE (grade 3-4) | 0.03 [0.00, 0.26] | | < 1 | | 0% | 1 study (1/-) | 99.9 % | NA | not evaluable | | non important | - |
| Vomiting AE (grade 3-4) | 1.55 [0.66, 3.64] | | < 1 | | 0% | 1 study (1/-) | 15.7 % | NA | not evaluable | | non important | - |
| Weight decreased AE (grade 3-4) | 0.98 [0.06, 15.76] | | < 1 | | 0% | 1 study (1/-) | 50.5 % | NA | not evaluable | | non important | - |
